Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open, Randomized,Positive Control, Multicenter Phase III Clinical Study of SHR A1904 for Injection Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patients With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma

NCT06649292 is registered in ClinicalTrials.gov with Shanghai Hengrui Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT06649292
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06649292 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open, Randomized,Positive Control, Multicenter Phase III Clinical Study of SHR A1904 for Injection Compared With Investigator's Choice of Therapy in Claudin18.2 Positive Patients With Second-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
Lead sponsor
Shanghai Hengrui Pharmaceutical Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
November 22, 2024
Completion date
March 20, 2028
Enrollment
524 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

second-line advanced or metastatic gastric or gastroesophageal junction adenocarcinoma